Clinical characteristics of patients with asymptomatic and symptomatic COVID-19 admitted to a tertiary referral centre in the Philippines

Anna Flor G. Malundo a,*, Cybele Lara R. Abad a, Maria Sonia S. Salamat a, Joanne Carmela M. Sandejas a, Jose Eladio G. Planta a, Jonnel B. Poblete b, Shayne Julieane L. Morales a, Ron Rafael W. Gabunada a, Agnes Lorraine M. Evasan a, Johanna Patricia A. Cañal c, Julian A. Santos c, Jeffrey T. Manto c, Raniv D. Rojo d, Eric David B. Ornos d, Mary Elise L. Severino d, Maria Elizabeth P. Mercado e, Marissa M. Alejandro a

a Division of Infectious Diseases, University of the Philippines–Philippine General Hospital, Manila, Philippines
b Department of Medicine, University of the Philippines–Philippine General Hospital, Manila, Philippines
c Department of Radiology, University of the Philippines–Philippine General Hospital, Manila, Philippines
d College of Medicine, University of the Philippines, Manila, Philippines
e Department of Clinical Epidemiology, Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines

A R T I C L E   I N F O

Keywords:
COVID-19
Philippines
Epidemiology
Asymptomatic
Severity

A B S T R A C T

Objectives: To describe the clinical profile and outcomes of hospitalized patients with coronavirus disease 2019 (COVID-19) across the spectrum of disease severity.
Methods: This retrospective study included adult patients with confirmed COVID-19 infection admitted to a referral hospital. Descriptive statistics, tests for trend, Kaplan–Meier curve and log-rank test were used to compare characteristics and outcomes across disease severity categories.
Results: Of 1500 patients with COVID-19, 14.8% were asymptomatic, 13.5% had mild disease, 36.6% had moderate disease, 12.3% had severe disease and 22.7% had critical disease. Asymptomatic patients were admitted for a concurrent condition or for isolation. Patients aged >60 years, male gender and with co-morbidities had more severe disease. Fever, cough, shortness of breath, malaise, gastrointestinal symptoms and decreased sensorium were more common in patients with severe disease. Bilateral pulmonary infiltrates were common (51.1%), with sicker patients having more abnormal findings. The overall mortality rate was 15.1%. Adopting a symptom-based strategy reduced the length of hospitalization from a median of 13 [interquartile range (IQR) 7–21] days to 9 (IQR 5–14) days.
Conclusion: The clinical profile and outcomes for this cohort of patients with COVID-19 was consistent with published reports. Asymptomatic infection was common, and universal testing may be a valuable strategy in the correct context, given the implications for infection control. A symptom-based strategy was found to reduce the length of hospitalization considerably.

Introduction

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and has resulted in a pandemic infecting more than 273 million people worldwide (World Health Organization, 2021a). With the pandemic in its second year, much research has been undertaken to understand viral pathogenesis, transmission, and risk factors for disease progression and mortality (World Health Organization, 2021b). Governments and hospitals have adapted to structural and resource limitations with changes in policies. However, despite this, the Philippines remains the most affected country in the Western Pacific Region, reporting the highest cumulative number of cases of COVID-19 and associated deaths as of 22 December 2021 (World Health Organization, 2021c).

Most published data on COVID-19 have originated from Western and high-income countries. The largest published study from the Philippines is a multi-centre study with 10,881 participants, which focused on neurologic manifestations among patients with COVID-19

* Corresponding author. A.F.G. Malundo. Division of Infectious Diseases, University of the Philippines–Philippine General Hospital, Taft Avenue, Ermita, Manila, National Capital Region, Philippines. Tel.: +63 02 8525 1062, +63 961 339 1325.
E-mail address: afgmalundo@up.edu.ph (A.F.G. Malundo).

https://doi.org/10.1016/j.ijregi.2022.02.002
Received 10 August 2021; Received in revised form 25 January 2022; Accepted 4 February 2022
2772-7076/© 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Another study investigated 500 patients from an infectious disease referral hospital in Manila, and compared the clinical profile and outcomes among healthcare workers (HCWs) and non-HCWs (Agrupis et al., 2021). Other studies from the Philippines described experiences early in the pandemic, had small study sizes, and excluded asymptomatic individuals (Edrada et al., 2020; Abad et al., 2021; Salamat et al., 2021; Soria et al., 2021). Approximately 25% of cases of COVID-19 are asymptomatic (Alene et al., 2021), and this population has the potential to drive community transmission and strain healthcare resources. At the University of the Philippines–Philippine General Hospital (UP-PGH), asymptomatic infections are often identified through universal testing (i.e. SARS-CoV-2 testing regardless of indication for admission or presence of symptoms). Due to uncertainties early in the pandemic, patients with mild COVID-19 and asymptomatic patients were sometimes admitted for monitoring. Aside from the excessive admissions, hospital capacity was also strained by implementation of the test-based strategy, which required two consecutive negative SARS-CoV-2 test results before discontinuation of transmission-based precautions and discharge of recovered patients. This policy was updated in July 2021, such that specific groups of patients could be discharged as long as significant clinical recovery was noted, and antipyretics were not required during the last 3 days of a 14-day isolation period (i.e. symptom-based strategy) (Philippine Society for Microbiology and Infectious Diseases et al., 2020).

This study aimed to describe the clinical characteristics and outcomes of the first 1500 adult inpatients with confirmed COVID-19 at UP-PGH with a view to prioritizing healthcare resources. The clinical predictors of mortality and disease progression have been analyzed in a separate paper.

Methods

Study design and setting

The medical records of adult inpatients with confirmed COVID-19 infection at UP-PGH, a tertiary-level COVID-19 referral hospital in Manila, the epicentre of the COVID-19 pandemic in the Philippines, were reviewed. The UP-Manila Ethics Review Board approved this study, including waiver of patient informed consent.

Study sample

The UP-PGH Registry of Admissions and Discharges was used to identify patients aged ≥19 years with confirmed COVID-19. Due to limited clinical information, patients who died or were discharged within 24 h of admission, patients who were transferred to another hospital, and patients whose medical records were unavailable for review during the time of analysis were excluded from this study. In total, 1500 consecutive inpatients from 12 March 2020 to 9 September 2020 with confirmed COVID-19 were included in this study Figure 1. shows the cohort selection process.

Definitions

A confirmed case of COVID-19 was defined as any patient with a positive reverse transcription polymerase chain reaction (RT-PCR) test for SARS-CoV-2 conducted at a testing facility accredited by the Department of Health. RT-PCR, which detects viral RNA in respiratory samples, is the current standard for the confirmation of acute SARS-CoV-2 infection (World Health Organization, 2020). RT-PCR has reported sensitivity of 0.68 (probability interval 0.63–0.73) and specificity of 0.99 (probability interval 0.98–1.00) (Kostoulas et al., 2021). False-negative results may be caused by poor-quality specimens; specimens taken late in the course of disease; inappropriate handling of specimens; and technical reasons, such as PCR inhibition or viral mutation (World Health Organization, 2020).

Severity of disease was classified at hospital admission, as follows:

- Asymptomatic – absence of COVID-19 symptoms and no evidence of pneumonia.
- Mild – presence of COVID-19 symptoms but no evidence of pneumonia.
- Moderate – presence of COVID-19 symptoms, and comorbidities such as hypertension, cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease (COPD), asthma, immunocompromising conditions (e.g. human immunodeficiency virus infection, chronic steroid use, active malignancy); or pneumonia but without need for oxygen support.
- Severe – presence of pneumonia, oxygen saturation ≤92% on room air and requiring oxygen support.
- Critical – acute respiratory distress syndrome, septic shock, on mechanical ventilation or admitted to the intensive care unit (Philippine Society for Microbiology and Infectious Diseases et al., 2020).

In-hospital mortality was defined as death during hospitalization, regardless of cause. Mortality rate was calculated as the number of deaths divided by the total number of cases.

Data collection

A group of physicians extracted data from medical records using a standard electronic data collection form. Chest x-ray images were reviewed by three radiologists on the study team. Missing data, inconsistencies and data accuracy were reviewed. Conflicting data were resolved by consensus.

Demographic data and information regarding co-morbid diseases, reasons for admission of asymptomatic patients, symptoms on presentation, vital signs on admission, severity of disease on admission, and results of diagnostic studies were collected. Outcomes such as length of hospital stay and mortality were recorded.

Data analysis

Counts and percentages were used to summarize categorical variables. The Shapiro–Wilk test was used to assess normality of continuous variables, and data are expressed as median and interquartile range (IQR), as appropriate. Univariate analyses, with the Cochran–Armitage test for trend for categorical variables and the Jonckheere–Terpstra trend test for continuous variables, were performed to compare parameters across the spectrum of disease severity. Post-hoc test (Conover) was performed for pairwise comparison of groups. The length of hospital
stay was compared by severity of disease, and after revision of the discharge criteria. Kaplan–Meier analysis with log-rank test was performed to compare 28-day mortality across the spectrum of disease severity categories. All tests were two-tailed, with \( P<0.05 \) considered to indicate statistical significance. Analyses were conducted using Microsoft Excel and MedCalc Statistical Software Version 19.7.4.

Results

Clinical characteristics

Of the 1500 participants, 53.0% were female (n=795) and 66.7% were aged <60 years (n=1001). The median age was 51 (IQR 34–63) years, with a bimodal age distribution as shown in Figure 2. More than half of the participants had co-morbid conditions (n=961, 64.1%), with hypertension being the most common (n=628, 41.9%). Three hundred and five (20.3%) participants were HCWs, and 12.3% (n=185) were pregnant. The demographic and clinical profile of the study cohort is shown in Table 1.

Of the study cohort, 81.0% (n=1215) were symptomatic and 19.0% (n=285) did not present with any symptoms suggestive of COVID-19. Of the latter, 215 (75.4%) were found to be COVID-19 positive on routine screening. Reasons for admission included obstetric management (n=162), surgery or procedure (n=17), cancer evaluation or chemotherapy (n=15), trauma (n=11) and other medical conditions (n=10). The remaining 70 patients were tested for SARS-CoV-2 as part of contact tracing (n=28), hospital surveillance (n=24), travel requirement (n=8), pre-employment (n=6) or for haemodialysis (n=4). However, 63 of the 285 (22.1%) patients who did not have COVID-19 symptoms were found to have subclinical disease with pneumonia on chest x-ray (n=61) or hypoxaemia requiring oxygen support (n=2). As a result, only 14.8% (n=222) of participants were assessed to be asymptomatic, while 13.5% (n=203), 36.6% (n=549), 12.3% (n=185) and 22.7% (n=341) had mild, moderate, severe and critical COVID-19, respectively.

Severity of disease increased progressively with age (Table 1). Males, smokers, drinkers (alcohol) and patients with co-morbidities (e.g. diabetes mellitus, hypertension, heart disease, chronic kidney disease, COPD, active pulmonary tuberculosis, cancer, pre-existing neurologic disease) tended to have more severe disease Table 2. shows that the majority of HCWs and pregnant women were asymptomatic or had mild disease. Furthermore, most of these patients were aged <60 years and did not have any co-morbidities.

Commonly reported symptoms were cough (50.1%), fever (46.9%) and shortness of breath (37.2%). The frequency of fever, cough, shortness of breath, malaise, nausea or vomiting, decreased appetite, diarrhoea, abdominal pain or discomfort, and decreased sensibility increased with severity of disease (Table 3; see Table S1 in the online supplementary material for comprehensive list of symptoms). Abnormal vital signs on admission were observed among those with severe and critical COVID-19, with higher respiratory rates, lower peripheral oxygen saturation and lower Glasgow Coma Scale scores (Table 3).

All asymptomatic patients underwent at least one laboratory test, while patients with severe or critical disease underwent extensive diagnostic evaluation (Table S2, see online supplementary material). Abnormal laboratory results were observed with increasing severity of disease (Table 3; also see Table S3 in the online supplementary material for the limits of normal haematologic and blood chemistries for adults). The majority (n=1424, 94.9%) of patients had a chest x-ray. More severe and critical cases had ground glass opacities, consolidation, and infiltrates affecting >50% of the lungs. Pleural effusion (6.7%) and pneumothorax (0.3%) were uncommon (see Table S1 in the online supplementary material for detailed radiographic findings).

Pairwise analysis did not show significant differences between mild and asymptomatic patients in terms of age, vital signs on admission and multiple laboratory parameters (Table S4, see online supplementary material).

Outcomes

The overall mortality rate was 15.1% (n=226). Greater severity of disease was associated with mortality (Table 3), as shown in the Kaplan–Meier survival curve (Figure 3). One asymptomatic patient died of nosocomial pneumonia after developing profound neutropenia following chemotherapy for acute leukaemia.

The overall median length of hospitalization was 12 (IQR 7–19) days, and was shorter for mild cases (Table 3). Change in the discharge guidelines resulted in a significant reduction (\( P<0.05 \)) in the overall length of hospitalization from a median of 13 (IQR 7–21) days to 9 (IQR 5–14) days. This was observed across all patient groups.

Discussion

This study validates published findings that have reported the following: (1) association between COVID-19, age and co-morbidities (Jin et al., 2020; Salva et al., 2020; Abad et al., 2021; Mishra et al., 2020; Salamat et al., 2021); (2) common clinical presentations including cough, fever and shortness of breath (Cao et al., 2020; Jin et al., 2020; Jutzieler et al., 2020; Salva et al., 2020; Wong et al., 2020; Abad et al., 2021; Salamat et al., 2021); and (3) overall mortality rate of 15% (Salva et al., 2020; Abad et al., 2021). In addition, this study highlights other important insights about COVID-19: (1) asymptomatic dis-
ease occurs frequently (14.8%) and is captured on routine evaluation; (2) COVID-19 has a bimodal age distribution; (3) HCWs are at high risk of COVID-19; and (4) a symptom-based strategy reduces the duration of hospitalization considerably.

COVID-19 in the Philippines has been reported to affect older age groups disproportionately (Haw et al., 2020). However, the findings of the present study showed a bimodal distribution of cases (Figure 2) with two distinct populations: a young, economically productive population and an older population. Studies have consistently shown old age as a significant risk factor for infection, hospitalization and adverse outcomes (Wu et al., 2020; Zhou et al., 2020; Garibaldi et al., 2021), presumably due to immunosenescence and increased prevalence of comorbidities (Perrotta et al., 2020; Bajaj et al., 2021; Chen et al., 2021). In the USA, hospitalization is almost twice as long for patients aged 65–74 years compared with those aged 50–64 years, and five times as long compared with patients aged 18–49 years (CDC COVID-19 Response Team, 2020; Garg et al., 2020). Quarantine restrictions in Manila preclude the elderly from leaving the household, mitigating their risk of acquiring COVID-19. However, if members of the same household frequently come and go, this may explain disease transmission and subsequent infection of the elderly. A meta-analysis reported an estimated household secondary attack rate from both asymptomatic (0.7%; 95% confidence interval (CI) 0–4.9%) and symptomatic (18.0%; 95% CI 14.2–22.1%) individuals (Madewell et al., 2020). It is hypothesized that the bimodal distribution may be indirect evidence of transmission of SARS-CoV-2 within households, where asymptomatic young adults drive community transmission and infect the elderly in the household.

### Table 1
Demographic and clinical profile of inpatients with confirmed coronavirus disease 2019 stratified based on severity of disease.

|                      | Asymptomatic (n=222) | Mild (n=203) | Moderate (n=549) | Severe (n=185) | Critical (n=341) | P-value |
|----------------------|----------------------|-------------|-----------------|----------------|-----------------|---------|
| **Age, years**       |                      |             |                 |                |                 |         |
| Median (IQR)         | 33 (27–38)           | 31 (28–42)  | 54 (43–64)      | 57 (46–67)     | 63 (53–71)      | <0.01   |
| ≥60, n (%)           | 14 (6.3)             | 0 (0)       | 206 (37.5)      | 81 (43.8)      | 198 (58.1)      | <0.01   |
| **Sex, n (%)**       |                      |             |                 |                |                 |         |
| Male                 | 45 (20.3)            | 79 (38.9)   | 267 (48.6)      | 104 (56.2)     | 210 (61.6)      | <0.01   |
| Co-existing condition, n (%) |             |             |                 |                |                 |         |
| Any co-morbid illness | 55 (24.8)           | 54 (26.6)   | 433 (78.9)      | 141 (76.2)     | 278 (81.5)      | <0.01   |
| Diabetes mellitus    | 10 (4.5)             | 0 (0)       | 158 (28.8)      | 59 (31.9)      | 102 (29.9)      | <0.01   |
| Hypertension         | 29 (13.1)            | 0 (0)       | 304 (55.4)      | 96 (51.9)      | 199 (58.4)      | <0.01   |
| Heart disease        | 1 (0.5)              | 0 (0)       | 84 (15.3)       | 30 (16.2)      | 55 (16.1)       | <0.01   |
| Chronic liver disease| 1 (0.5)              | 1 (0.5)     | 5 (0.9)         | 0 (0)          | 5 (1.5)         | 0.25    |
| Chronic kidney disease| 2 (0.9)            | 2 (1.0)     | 57 (10.4)       | 29 (15.7)      | 24 (7.0)        | <0.01   |
| COPD                 | 0 (0)                | 0 (0)       | 10 (1.8)        | 6 (3.2)        | 13 (3.8)        | <0.01   |
| Asthma               | 3 (1.4)              | 24 (11.8)   | 36 (6.6)        | 12 (6.5)       | 16 (4.7)        | 0.96    |
| Active PTB           | 0 (0)                | 1 (0.5)     | 15 (2.7)        | 10 (5.4)       | 14 (4.1)        | <0.01   |
| HIV                  | 1 (0.5)              | 0 (0)       | 7 (1.3)         | 0 (0)          | 0 (0)           | 0.39    |
| **COPD, chronic obstructive pulmonary disease; PTB, pulmonary tuberculosis; IQR, interquartile range.** |

### Table 2
Clinical profile and outcomes of healthcare workers and pregnant inpatients with coronavirus disease 2019 at the University of the Philippines–Philippine General Hospital.

| Healthcare workers (n=305) | Pregnant (n=185) |
|----------------------------|-----------------|
| **Age, years**             |                 |
| Median (IQR)               |                 |
| <60, n (%)                 | 283 (92.8)      | 185 (100) |
| ≥60, n (%)                 | 22 (7.2)        | 0 (0)    |
| **Sex, n (%)**             |                 |
| Male                       | 126 (41.3)      | Not applicable |
| Concurrent conditions, n (%)|                 |
| Presence of any co-morbid illness | 138 (45.2) | 30 (16.2) |
| Smoker                     | 25 (8.2)        | 6 (3.2)  |
| Drinker (alcohol)          | 50 (16.4)       | 7 (3.8)  |
| History of illicit drug use| 1 (0.3)         | 1 (0.5)  |
| **IQR, interquartile range.** |

In the USA, hospitalization is almost twice as long for patients aged 65–74 years compared with those aged 50–64 years, and five times as long compared with patients aged 18–49 years (CDC COVID-19 Response Team, 2020; Garg et al., 2020). Quarantine restrictions in Manila preclude the elderly from leaving the household, mitigating their risk of acquiring COVID-19. However, if members of the same household frequently come and go, this may explain disease transmission and subsequent infection of the elderly. A meta-analysis reported an estimated household secondary attack rate from both asymptomatic (0.7%; 95% confidence interval (CI) 0–4.9%) and symptomatic (18.0%; 95% CI 14.2–22.1%) individuals (Madewell et al., 2020). It is hypothesized that the bimodal distribution may be indirect evidence of transmission of SARS-CoV-2 within households, where asymptomatic young adults drive community transmission and infect the elderly in the household.
Table 3
Clinical characteristics on admission and outcomes of patients with coronavirus disease 2019 at University of the Philippines-Philippine General Hospital.

| Severity of disease on admission | Asymptomatic (n=222) | Mild (n=203) | Moderate (n=549) | Severe (n=185) | Critical (n=341) | P-value |
|----------------------------------|----------------------|-------------|-----------------|----------------|-----------------|---------|
| Symptoms, n (%)                  |                      |             |                 |                |                 |         |
| Fever                            | -                    | 97 (47.8)   | 269 (49.0)      | 108 (58.4)     | 229 (67.2)      | <.0001  |
| Cough                            | -                    | 91 (44.8)   | 285 (51.9)      | 132 (71.4)     | 244 (71.6)      | <.0001  |
| Shortness of breath              | -                    | 40 (19.7)   | 145 (26.4)      | 130 (70.3)     | 243 (71.3)      | <.0001  |
| Malaise/fatigue/                 | -                    |              |                 |                |                 |         |
| generalized weakness            | -                    | 50 (24.6)   | 132 (24.0)      | 58 (31.4)      | 105 (30.8)      | <.0001  |
| Diarrhoea                        | -                    | 44 (21.7)   | 76 (13.8)       | 27 (14.6)      | 52 (15.2)       | <.0001  |
| Nausea or vomiting               | -                    | 7 (3.4)     | 23 (4.2)        | 14 (7.6)       | 21 (6.2)        | <.0001  |
| Decreased appetite               | -                    | 9 (4.4)     | 44 (8.0)        | 33 (17.8)      | 75 (22.0)       | <.0001  |
| Abdominal pain/discomfort        | -                    | 9 (4.4)     | 26 (4.7)        | 9 (4.9)        | 14 (4.1)        | 0.048   |
| Change or loss in taste          | -                    | 17 (8.4)    | 39 (7.1)        | 14 (7.6)       | 24 (7.0)        | 0.012   |
| Decreased sensorium              | -                    | 5 (2.5)     | 23 (4.2)        | 7 (3.8)        | 53 (15.5)       | <.0001  |
| Vitals signs, median (IQR)       |                      |             |                 |                |                 |         |
| Systolic blood pressure, mmHg   | 120 (110-130)        | 120 (110-130)| 130 (120-140)  | 130 (120-144)  | 130 (113-145)  | <.0001  |
| Diastolic blood pressure, mmHg   | 80 (70-80)           | 78 (70-80)  | 80 (70-85)      | 80 (70-85)     | 80 (70-85)      | 0.069   |
| Heart rate, beats/min           | 85 (78-92)           | 83 (76-91)  | 84 (78-92)      | 90 (80-102)    | 98 (85-112)     | <.0001  |
| Respiratory rate, breaths/min   | 20 (19-20)           | 20 (18-20)  | 20 (20-20)      | 22 (20-24)     | 26 (23-26)      | <.0001  |
| Temperature, °C                  | 36.5 (36.4-36.9)     | 36.5 (36.1-36.8)| 36.6 (36.2-37.0)| 36.7 (36.5-37.3)| 36.7 (36.3-37.0)| <.0001  |
| Peripheral O2 saturation, %      | 98 (97-99)           | 98 (97-99)  | 98 (96-98)      | 95 (91-97)     | 92 (81-96)      | <.0001  |
| Glasgow Coma Scale score         | 15 (15-15)           | 15 (15-15)  | 15 (15-15)      | 15 (15-15)     | 15 (15-15)      | <.0001  |

Laboratory findings

Complete blood count, median (IQR)

| Parameter                        | Value             |
|----------------------------------|-------------------|
| Haemoglobin, g/L                 | 127 (117-137)     |
| White blood cells, x10^9/L       | 10.3 (8.0-12.7)   |
| Neutrophils, %                   | 70.0 (63.3-77.6)  |
| ALC, x10^9/L                     | 1.97 (1.57-2.48)  |
| Platelets, x10^9/L               | 284 (237-347)     |
| pO2 and FiO2 ratio               | 467 (424-511)     |
| Blood chemistry, median (IQR)    |                   |
| Serum creatinine, μmol/L         | 56.0 (46.0-74.5)  |
| Alanineaminotransferase, IU/L    | 18.0 (12.0-34.0)  |
| Albumin, g/L                     | 39.0 (35.4-48.0)  |
| Total bilirubin, mg/dL           | 0.57 (0.42-0.87)  |
| Inflammatory markers, median (IQR)|                 |
| Lactate dehydrogenase, U/L       | 233 (203-279)     |
| Serum ferritin, ng/mL            | 89 (38-229)       |
| Serum procalcitonin, ng/mL       | 0.07 (0.04-0.11)  |
| C-reactive protein, n (%)        | 0.62 (0.32-1.42)  |

Chest radiograph, n (%)              69 (31.1)

Pulmonary infiltrates

Bilateral                           69 (31.1)
>50% of lungs                       69 (31.1)
Limited-periphery                   69 (31.1)

Density

Ground glass                        69 (31.1)
Consolidation                       69 (31.1)
Mortality, n (%)                    69 (31.1)

Length of hospital stay, median (IQR)| 4 (3–9)  |


The present findings also reflect global trends of increasing infection among younger, economically productive age groups (Salvatore et al., 2020). This can be attributed to higher exposure related to the resumption of activities in schools and workplaces, non-compliance with restrictions and/or the presence of co-morbidities (Czeisler et al., 2020; Salvatore et al., 2020). Since HCWs and pregnant patients comprised almost one-quarter of the study population (Table 2), the data are skewed, leading to a younger cohort of patients.

It is possible that many infections among the HCWs in this study were detected because of better access to testing, lower threshold for...
with positivity rates ranging from 0.03% to 4.5% (Sastry et al., 2020; Nakamura and Itoi, 2021; Saidel-Odes et al., 2021). Positivity rates were influenced by local prevalence and the level of community transmission. Data on the cost-effectiveness of universal screening are limited. However, in areas where the prevalence rate and level of community transmission are high [i.e. ≥100 new cases per 100,000 persons in the past 7 days, or ≥10% positive nucleic acid amplification tests during the past 3 days (Centers for Disease Control and Prevention, 2021)], this may be an acceptable strategy to guide bed allocation and use of PPE, and to prevent unnecessary quarantine of exposed HCWs and nosocomial transmission.

Changes in the local guidelines affected the length of hospitalization of patients with COVID-19 significantly at UP-PGH. The implementation of a symptom-based strategy resulted in a shorter duration of hospitalization, especially for patients with mild disease. A US study showed similar results with excess length of stay for acute care as well as extra cost for test-based vs symptom-based isolation strategies (Wu et al., 2021). Studies have shown that RT-PCR positivity for SARS-CoV-2 may persist beyond infectivity, and that viable SARS-CoV-2 was not isolated among patients beyond 8 days since symptom onset (Bullard et al., 2020; Xiao et al., 2020). The shorter length of stay had several positive consequences, including allocation of badly needed beds, and decreased cost for those who were admitted. However, the need to reallocate hospital beds must be balanced with the possibility of disease transmission from individuals recovering from COVID-19. Clinical data for patients with severe or critical disease or immunocompromised patients are limited, and viral shedding can theoretically be longer. As such, isolation was extended to 21 days for this subpopulation of patients (Philippine Society for Microbiology and Infectious Diseases et al., 2020). As more is learned about the mechanics of transmission of the variants of concern, guidance regarding symptom-based isolation protocols may also evolve.

**Implications for clinical practice**

The economic impact and healthcare burden of COVID-19 necessitates evidence-based changes in policies to mitigate these problems. The study findings show that: (1) blood tests among asymptomatic cases and patients with mild COVID-19 are likely to be unnecessary; (2) universal testing in areas with a high level of community transmission can guide resource and bed allocation; and (3) a symptom-based isolation protocol can address issues of limited bed capacity.

**Study limitations**

This study has limitations inherent to its retrospective nature, including the possibility of information and misclassification bias. However, any information bias from missing data was mitigated by the use of a hospital clinical pathway for patients with COVID-19 which guided systematic recording of clinical information. Misclassification bias could have resulted if asymptomatic patients were found to have pneumonia on chest x-ray (i.e. 30% of asymptomatic patients did not have imaging, and may have been misclassified as asymptomatic rather than moderate cases, underestimating the proportion of patients with moderate disease). National guidelines were used for the classification of COVID-19 severity, but these are comparable with international definitions. The authors were unable to identify presymptomatic patients as asymptomatic patients were not followed-up to assess if they developed symptoms within 14 days of a positive SARS-CoV-2 test result. In addition, the authors were unable to perform genomic analysis, which could have helped evaluate transmission dynamics. These findings may not be generalizable due to differences between populations, differences in hospital policies, differences in clinical practice, and differences in the level of community transmission. Despite these limitations, however, this study has several strengths. A large cohort of consecutive patients was assessed, including a good proportion of patients with asymptomatic disease (this group is often excluded from analysis of hospital-
ized patients). In addition, the authors were able to discuss changes in hospital policy over the study period which impacted infection control strategies and patient outcomes.

**Conclusion**

The clinical profile of patients with COVID-19 in this study was consistent with published reports globally. Asymptomatic cases and patients with mild COVID-19 share similar clinical features, while markers of inflammation increase and signs of organ dysfunction become more evident in patients with severe and critical disease. Asymptomatic COVID-19 is common, and blood tests are likely to be unnecessary. Universal testing may be a valuable strategy in areas of high community transmission, given its implications for infection control. The overall mortality rate of COVID-19 was high at 15.1%. The symptom-based strategy shortened the length of hospitalization and should be recommended.

**Acknowledgements**

The authors wish to thank Dr Kenneth Wilson O. Lim, Dr Cécile Anne M. Tuazon, Dr Paula Victoria Catherine Y. Cheng, Dr Henry Winston C. Li, Dr Lester Jan A. Olumba, Dr Jamila Lynn O. Compuesto, Dr Kenzle Denise G. Monsanto and Ms. Lozzel D. Villadare for their assistance in data collection. In addition, the authors wish to thank UP-PGH Division of Infectious Diseases, especially Dr Jodor A. Lim, Dr Regina P. Berba, Dr Christine Peñalosa-Ramos, Dr Karla Kristel A. Bañares, Dr Samantha S. Bartolo, Dr Bernard A. Demot, Dr Honey Jane B. Limos, Dr Marlon S. Areegono, Dr Susana V. Buno, Dr Christina C. Tan, Dr Mary Grace C. Astudillo, Dr Emmeline B. Borillo, Dr Cherry Fainty M. Budao, Dr Mark John F. Festein, Dr Mark Ramon Victor B. Llanes, Dr Joe Rich P. Macrohon, and Dr Ma Patricia G. Virata for assisting in the retrieval of data, and for providing the resources and support needed to complete the study. Finally, the authors wish to thank UP-PGH and the Department of Medicine for their support for COVID-19-related research.

**Conflict of interest statement**

None declared.

**Funding**

This research did not receive any specific grants from funding agencies in the public, commercial or not-for-profit sectors.

**Supplemental materials**

Supplemental material associated with this article can be found in the online version, at doi:10.1016/j.jiregi.2022.02.002.

**References**

Abad CL, Lansang MAD, Cordero CP, Viray EDE, Tiangco BJ, Belle JAG, et al. Early experience with COVID-19 patients in a private tertiary hospital in the Philippines: implications on surge capacity, healthcare systems response, and clinical care. Clin Epidemiol Glob Health 2021;10:

Agrupis KA, Smith C, Suzuki S, Villanueva AM, Ariyoshi K, Solarte R, et al. Epidemiological and clinical characteristics of the first 500 confirmed COVID-19 inpatients in a tertiary infectious disease referral hospital in Manila, Philippines. Trop Med Health 2021;49:48.

Aleene M, Yismaw L, Asseme MA, Ketema DB, Mengist B, Kasseie B, et al. Magnitude of asymptomatic COVID-19 cases throughout the course of infection: a systematic review and meta-analysis. PLoS One 2021;16:

Bajaj V, Gadi N, Sphiltman AP, Wu MC, Choi CH, Moulton VR. Ageing, immunity, and COVID-19: how age influences the host immune response to coronavirus infection? Front Physiol 2021;12:

Ballard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis 2019;69:

Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J Med Virol 2020;92:1449–50.

CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) – United States, February 12–16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:343–6.

Centers for Disease Control and Prevention. Operational strategy for K-12 schools through phased prevention. Atlanta, GA: CDC; 2021.

Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev 2021;65:

Clevenger ML, Tyman MA, Howard ME, Honeycutt S, Fairman DP, et al. Public attitudes, behaviors, and beliefs related to COVID-19, stay-at-home orders, nonessential business closures, and public health guidance – United States, New York City, and Los Angeles, May 5–12, 2020. MMWR Morb Mortal Wkly Rep 2020;69:751–8.

Eddra SM, Lopez EB, Villaraza JB, Salva Villaraza EP, Pag-asa BP, Smith C, et al. COVID-19 infections in the Philippines: a case report. Trop Med Health 2020;48:21.

El-Boghdady K, Wong DQ, Owen R, Neuman MD, Pacocha S, Carlisle JB, et al. Risks to healthcare workers following tracheal intubation of patients with COVID-19: a prospective international cohort study. Anaesthesia 2020;75:1437–47.

Espiritu AI, Sy MCC, Anlakan VM, Jamora RDG. COVID-19 outcomes of 10,881 patients: retrospective study of neurological symptoms and associated manifestations (Philippine CORONA Study). J Neurol Transm 2021;128:1687–703.

Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Hoeltzel B, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 – COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:856–68.

Garibaldi BT, Fiksel J, Moschelli J, Robinson ML, Routhiedze M, Perin J, et al. Patient trajectories among persons hospitalized for COVID-19: a cohort study. Ann Intern Med 2021;174:33–41.

Gómez-Ososa SA, Franco OH, Rojas LL, Riquindin PF, Roa-Díaz ZM, Wysnnman BM, et al. COVID-19 in health-care workers: a living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. Am J Epidemiol 2021;190:161–75.

Hansell DM, Bankier AA, MacMahon H, McCloud TC, Müller NL, Remy J. Fleischer Society: Glossary of Terms for Thoracic Imaging. Radiology 2008;246(3):697–722. doi:10.1148/radol.246.20070112.

Hajj-Majidi M, Kamran A, Salama R, Bhuiyan M, et al. COVID-19 and non-communicable diseases: a systematic review and meta-analysis. Iran J Med Sci 2020;45:163–73.

Hansell DM, Bankier AA, MacMahon H, McCloud TC, Müller NL, Remy J. Fleischer Society: Glossary of Terms for Thoracic Imaging. Radiology 2008;246(3):697–722. doi:10.1148/radol.246.20070112.

Hajj-Majidi M, Kamran A, Salama R, Bhuiyan M, et al. COVID-19 and non-communicable diseases: a systematic review and meta-analysis. Iran J Med Sci 2020;45:163–73.

Hajj-Majidi M, Kamran A, Salama R, Bhuiyan M, et al. COVID-19 and non-communicable diseases: a systematic review and meta-analysis. Iran J Med Sci 2020;45:163–73.

Hajj-Majidi M, Kamran A, Salama R, Bhuiyan M, et al. COVID-19 and non-communicable diseases: a systematic review and meta-analysis. Iran J Med Sci 2020;45:163–73.

Hajj-Majidi M, Kamran A, Salama R, Bhuiyan M, et al. COVID-19 and non-communicable diseases: a systematic review and meta-analysis. Iran J Med Sci 2020;45:163–73.

Hajj-Majidi M, Kamran A, Salama R, Bhuiyan M, et al. COVID-19 and non-communicable diseases: a systematic review and meta-analysis. Iran J Med Sci 2020;45:163–73.

Hajj-Majidi M, Kamran A, Salama R, Bhuiyan M, et al. COVID-19 and non-communicable diseases: a systematic review and meta-analysis. Iran J Med Sci 2020;45:163–73.

Hajj-Majidi M, Kamran A, Salama R, Bhuiyan M, et al. COVID-19 and non-communicable diseases: a systematic review and meta-analysis. Iran J Med Sci 2020;45:163–73.
Soria MLI, Quiwa L, MaKJ Calvario, Duya JE, Punongbayan R, Ting FI. The Philippine Coronavirus Disease 2019 (COVID-19) Profile Study: clinical profile and factors associated with mortality of hospitalized patients. Philipp J Intern Med 2021;59:37-58.

Wong X, Pan Z, Cheng Z. Association between 2019-nCoV transmission and N95 respirator use. J Hosp Infect 2020;105:104-5.

Wong CKH, Wong JYH, Tang EHM, Au CH, Wai AKC. Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis. Sci Rep 2020;10:19765.

World Health Organization. Weekly epidemiological update on COVID-19 — 21 December 2021. Geneva: WHO; 2021a Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—21-december-2021 (accessed 28 December 2021).

World Health Organization. Global research on coronavirus disease (COVID-19). Geneva: WHO; 2021b Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov (accessed 28 December 2021).

World Health Organization. COVID-19 situation report for the Western Pacific Region #84: 15 December 2021—21 December 2021. Geneva: WHO; 2021c Available at: https://www.who.int/western-pacific/publications/m/item/covid-19-situation-report—for-the-western-pacific-region-84-15-december-2021—21-december-2021 (accessed 28 December 2021).

World Health Organization. Diagnostic testing for SARS-CoV-2 : Interim Guidance 11. Geneva: WHO; 2020 Available at https://www.who.int/publications/m/item/diagnostic-testing-for-sars-cov-2 (accessed 25 January 2022).

Wu C, Chen X, Cai Y, Xia J, Xing Zhou, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934.

Wu C, Glass S, Demars S, Tulloch-Palomino LG, Wander PL. Estimated excess acute-care length of stay and extra cost of testing-based versus symptom-based isolation strategies among veterans hospitalized with coronavirus disease 2019 (COVID-19) discharging to a congregate setting. Infect Control Hosp Epidemiol 2021;42:356–8.

Xiao AT, Tong XY, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. Clin Infect Dis 2020;71:2249–51.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.